{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:38:28Z","timestamp":1770741508378,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"46","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T00:00:00Z","timestamp":1633132800000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.vaccine.2020.09.056","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T03:20:39Z","timestamp":1601608839000},"page":"7246-7257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3)"],"prefix":"10.1016","volume":"38","author":[{"given":"Sachiko","family":"Ezoe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirianne Marie Q.","family":"Palacpac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohhei","family":"Tetsutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouji","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Taira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumiyuki","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiko","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyotheeswara R.","family":"Edula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Tougan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken J.","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Myoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Horii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.09.056_b0005","series-title":"World Malaria Report 2019","author":"WHO","year":"2019"},{"key":"10.1016\/j.vaccine.2020.09.056_b0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.chom.2018.06.008","article-title":"Malaria vaccines: recent advances and new horizons","volume":"24","author":"Draper","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2020.09.056_b0015","doi-asserted-by":"crossref","first-page":"9751471","DOI":"10.1155\/2019\/9751471","article-title":"Prospects for malaria vaccines: pre-erythrocytic stages, blood stages, and transmission-blocking stages","volume":"2019","author":"Zheng","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.vaccine.2020.09.056_b0020","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(19)30937-7","article-title":"RTS,S malaria vaccine pilots in three African countries","volume":"393","author":"Adepoju","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.09.056_b0025","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.3389\/fmicb.2019.02712","article-title":"Plasmodium falciparum blood stage antimalarial vaccines: an analysis of ongoing clinical trials and new perspectives related to synthetic vaccines","volume":"10","author":"Salamanca","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2020.09.056_b0030","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.parint.2010.05.002","article-title":"Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36","volume":"59","author":"Horii","year":"2010","journal-title":"Parasitol Int"},{"issue":"5","key":"10.1016\/j.vaccine.2020.09.056_b0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064073","article-title":"Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36","volume":"8","author":"Palacpac","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.09.056_b0040","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1383-5769(02)00042-9","article-title":"Differential localization of processed fragments of Plasmodium falciparum serine repeat antigen and further processing of its N-terminal 47 kDa fragment","volume":"51","author":"Li","year":"2002","journal-title":"Parasitol Int"},{"key":"10.1016\/j.vaccine.2020.09.056_b0045","doi-asserted-by":"crossref","first-page":"47533","DOI":"10.1074\/jbc.M207145200","article-title":"Serine repeat antigen (SERA5) is predominantly expressed among the SERA multigene family of Plasmodium falciparum, and the acquired antibody titers correlate with serum inhibition of the parasite growth","volume":"277","author":"Aoki","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2020.09.056_b0050","doi-asserted-by":"crossref","first-page":"47524","DOI":"10.1074\/jbc.M206974200","article-title":"A subset of Plasmodium falciparum SERA genes are expressed and appear to play an important role in the erythrocytic cycle","volume":"277","author":"Miller","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2020.09.056_b0055","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1128\/IAI.00405-07","article-title":"Evidence for a common role for the serine-type Plasmodium falciparum serine repeat antigen proteases: implications for vaccine and drug design","volume":"75","author":"McCoubrie","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.09.056_b0060","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/mmi.12941","article-title":"Plasmodium falciparum SERA5 plays a non-enzymatic role in the malarial asexual blood-stage lifecycle","volume":"96","author":"Stallmach","year":"2015","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.vaccine.2020.09.056_b0065","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.vaccine.2011.12.124","article-title":"Geographic differentiation of polymorphism in the Plasmodium falciparum malaria vaccine candidate gene SERA5","volume":"30","author":"Tanabe","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.056_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098460","article-title":"Protective epitopes of the Plasmodium falciparum SERA5 malaria vaccine reside in intrinsically unstructured N-terminal repetitive sequences","volume":"9","author":"Yagi","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.09.056_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006453","article-title":"The Plasmodium falciparum pseudoprotease SERA5 regulates the kinetics and efficiency of malaria parasite egress from host erythrocytes","volume":"13","author":"Collins","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2020.09.056_b0080","doi-asserted-by":"crossref","first-page":"9736","DOI":"10.1074\/jbc.RA117.001540","article-title":"Calcium-dependent phosphorylation of Plasmodium falciparum serine repeat antigen 5 triggers merozoite egress","volume":"293","author":"Iyer","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2020.09.056_b0085","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1038\/s41598-019-44542-3","article-title":"Plasmodium pseudo-tyrosine kinase-like binds PP1 and SERA5 and is exported to host erythrocytes","volume":"9","author":"Gnangnon","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2020.09.056_b0090","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1074\/jbc.M112.411934","article-title":"Characterization of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) and its role in microneme secretion during erythrocyte invasion","volume":"288","author":"Bansal","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2020.09.056_b0095","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1038\/s41598-018-23194-9","article-title":"Molecular camouflage of Plasmodium falciparum merozoites by binding of host vitronectin to P47 fragment of SERA5","volume":"8","author":"Tougan","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2020.09.056_b0100","doi-asserted-by":"crossref","first-page":"34363","DOI":"10.1038\/srep34363","article-title":"Antibody titres and boosting after natural malaria infection in BK-SE36 vaccine responders during a follow-up study in Uganda","volume":"6","author":"Yagi","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2020.09.056_b0105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2020.09.056_b0110","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.4161\/hv.24715","article-title":"The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV\u2122 review","volume":"9","author":"Eng","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.09.056_b0115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-1-4939-6445-1_2","article-title":"Development of the CpG adjuvant 1018: a case study","volume":"1494","author":"Campbell","year":"2017","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2020.09.056_b0120","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1600-065X.2010.00978.x","article-title":"Use of defined TLR ligands as adjuvants within human vaccines","volume":"239","author":"Duthie","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2020.09.056_b0125","doi-asserted-by":"crossref","first-page":"6734","DOI":"10.1016\/j.vaccine.2012.08.074","article-title":"Revaccination with Fendrix\u00ae or HBVaxPro\u00ae results in better response rates than does revaccination with three doses of Engerix-B\u00ae in previous non-responders","volume":"30","author":"Hoebe","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.056_b0130","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1016\/j.vaccine.2014.06.065","article-title":"Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer","volume":"32","author":"Scheiermann","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.056_b0135","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1586\/14760584.2014.863715","article-title":"Recent progress concerning CpG DNA and its use as a vaccine adjuvant","volume":"13","author":"Shirota","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2020.09.056_b0140","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.4049\/jimmunol.166.4.2372","article-title":"Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs","volume":"166","author":"Verthelyi","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.09.056_b0145","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.4049\/jimmunol.168.4.1659","article-title":"CpG oligodeoxynucleotides as vaccine adjuvants in primates","volume":"168","author":"Verthelyi","year":"2002","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2020.09.056_b0150","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4161\/hv.22950","article-title":"TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36\/AHG malaria vaccine in nonhuman primate models","volume":"9","author":"Tougan","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.09.056_b0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002940","article-title":"Phase 1 trial of AMA1-C1\/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria","volume":"3","author":"Mullen","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.09.056_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046094","article-title":"Phase 1 study in malaria na\u00efve adults of BSAM2\/Alhydrogel\u00ae+CPG 7909, a blood stage vaccine against P. falciparum malaria","volume":"7","author":"Ellis","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2020.09.056_b0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008787","article-title":"Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1\/Alhydrogel with and without CPG 7909 in malaria na\u00efve adults","volume":"5","author":"Ellis","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.09.056_b0170","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.vaccine.2018.03.067","article-title":"Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults","volume":"36","author":"Hyer","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.09.056_b0175","first-page":"225","article-title":"Autoantibodies and liver disease: uses and abuses","volume":"24","author":"Zeman","year":"2010","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.vaccine.2020.09.056_b0180","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/art.10558","article-title":"The American college of rheumatology ad hoc committee on immunologic testing guidelines. Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests","volume":"47","author":"Kavanaugh","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.vaccine.2020.09.056_b0185","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.jaip.2017.06.033","article-title":"Evidence refuting the existence of autoimmune\/autoinflammatory syndrome induced by adjuvants (ASIA)","volume":"5","author":"Ameratunga","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.vaccine.2020.09.056_b0190","first-page":"360","article-title":"Preclinical studies on a new vaccine formulation of BK-SE36, a malaria vaccine candidate","volume":"61","author":"Palacpac","year":"2015","journal-title":"JMJ"},{"key":"10.1016\/j.vaccine.2020.09.056_b0195","doi-asserted-by":"crossref","first-page":"912","DOI":"10.4269\/ajtmh.2001.65.912","article-title":"Natural human immunoglobulin G subclass responses to Plasmodium falciparum serine repeat antigen in Uganda","volume":"65","author":"Okech","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2020.09.056_b0200","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12936-016-1146-4","article-title":"Antibody levels against GLURP R2, MSP1 block 2 hybrid and AS202.11 and the risk of malaria in children living in hyperendemic (Burkina Faso) and hypo-endemic (Ghana) areas","volume":"15","author":"Adu","year":"2016","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2020.09.056_b0205","doi-asserted-by":"crossref","first-page":"33094","DOI":"10.1038\/srep33094","article-title":"The association between naturally acquired IgG subclass specific antibodies to the PfRH5 invasion complex and protection from Plasmodium falciparum malaria","volume":"6","author":"Weaver","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2020.09.056_b0210","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41541-020-0160-2","article-title":"Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial","volume":"5","author":"Blank","year":"2020","journal-title":"npj Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2020.09.056_b0215","doi-asserted-by":"crossref","first-page":"pii: E267","DOI":"10.3390\/pharmaceutics12030267","article-title":"Characteristic of K3 (CpG-ODN) as a transcutaneous vaccine formulation adjuvant","volume":"12","author":"Ito","year":"2020","journal-title":"Pharmaceutics"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20312275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20312275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:49:45Z","timestamp":1759402185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20312275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":43,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0264410X20312275"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.09.056","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.09.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}